ライフサイエンスコーパス: mania

1 se processes were central to the etiology of mania.

2 indings from a first such study of late-life mania.

3 erity who are likely to be treated for acute mania.

4 were more frequently studied than for acute mania.

5 ure, as well as efficacy in a mouse model of mania.

6 depression may reflect differential risk of mania.

7 cantly higher risk of incident and recurrent mania.

8 r characterized by periods of depression and mania.

9 ted the effects of recent stressors on adult mania.

10 tient treatment, such as active psychosis or mania.

11 chronic recurrent episodes of depression and mania.

12 apy was associated with an increased risk of mania.

13 +LIT/VAL outperformed placebo+LIT/VAL for RR-mania.

14 and motivation in children at high risk for mania.

15 ion of behavioral features characteristic of mania.

16 t adolescence as the peak period of onset of mania.

17 he behavioral manifestations seen in bipolar mania.

18 ractivity, a frequently used animal model of mania.

19 of illness and to identify any hypomania or mania.

20 and least pervasive in bipolar disorder and mania.

21 the criterion standard for animal models of mania.

22 how and when to utilize this intervention in mania.

23 to examine correlates of treatment-emergent mania.

24 recovered from mania, but 73.3% relapsed to mania.

25 et of treatment and a measure of response in mania.

26 ildhood IQ predicted increased risk of adult mania.

27 a GSK-3beta inhibitor in this mouse model of mania.

28 ar depression without increasing the risk of mania.

29 (2) Medical conditions that mimic mania.

30 er and concerns about increasing the risk of mania.

31 ntered in the treatment of acute episodes of mania.

32 omising research regarding the use of ECT in mania.

33 igine+valproate, outperformed placebo for RR-mania.

34 evelopment of novel therapeutics for bipolar mania.

35 a novel approach to the treatment of bipolar mania.

36 tivity or energy" as a primary criterion for mania.

37 s known to cause switches from depression to mania.

38 ractive reward processing network, underlies mania.

39 individual were used to compare the rate of mania 0-3 months and 3-9 months after the start of antid

40 sedation (7.7%) in the open-label period and mania (11.9% of the placebo group compared with 4.0% of

41 for depression, 1.83 (95% CI=1.72-1.94); for mania, 4.35 (95% CI=3.67-5.16); for delirium, confusion,

42 tress responsivity are prominent symptoms of mania, a behavioral state common to schizophrenia and bi

43 group had a better outcome compared with the mania absent and chronic mania groups (12-point and 8-po

44 owed 2 discontinuities demarcating 3 groups: mania absent, episodic mania, and chronic mania (manic/h

45 and/or a history of postpartum psychosis or mania according to DSM or ICD criteria or the Research D

46 ly and independently associated with current mania (adjusted odds ratio 3.49, 95% confidence interval

47 D), which is characterized by depression and mania, affects 1-2% of the world population.

48 Psychosis or mania after childbirth is a psychiatric emergency with r

49 sulted in hyperactivity reminiscent of human mania, alterations in brain pathways that have been impl

50 l phenotypes reminiscent of aspects of human mania, ameliorated by antimania drugs lithium and valpro

51 tween methylphenidate and treatment-emergent mania among patients with bipolar disorder who were conc

52 gative consequences is a defining feature of mania and addiction, and numerous brain regions have bee

53 es of the dimensions and factor structure of mania and bipolar depression and (2) longitudinal studie

54 It is present in mania and bipolar depression, but data are equivocal for

55 f isolated behaviors and domains involved in mania and bipolar disorder will ultimately inform moveme

56 ing the dopamine synthesis and/or release in mania and DAT blockade in bipolar depression.

57 Hazard ratios were similar for mania and depression events (0.30 and 0.33, respectively

58 and is required to mediate endophenotypes of mania and depression in rodents.

59 iscoveries of pharmacological treatments for mania and depression several decades ago, relatively lit

60 Separate inheritance of mania and depression together with high rates of clinica

61 t of bipolar disorders to prevent relapse of mania and depression, but many patients do not have a re

62 ten abstracted by separate animal models for mania and depression.

63 sease characterized by recurrent episodes of mania and depression.

64 at is characterized by recurrent episodes of mania and depression.

65 tric illness marked by recurrent episodes of mania and depression.

66 characterized by extreme mood swings between mania and depression.

67 order characterized by recurrent episodes of mania and depression.

68 is characterized by intermittent episodes of mania and depression; without treatment, 15% of patients

69 dings may lead to new methods for preventing mania and for developing novel therapeutic interventions

70 Although mania and hypomania define bipolar disorder, depressive

71 ed as a coprimary symptom, the prevalence of mania and hypomania was reduced.

72 ntified in the DSM-5 as cardinal symptoms of mania and hypomania.

73 pine are effective in the treatment of acute mania and lamotrigine is effective at treating and preve

74 opposite to the direction seen in bipolar I mania and may therefore be state dependent, the observed

75 ely ill patients with schizophrenia, bipolar mania and MDD compared with controls (P<0.01).

76 re was no evidence for cross-transmission of mania and MDEs (OR=.7, CI:.5-1.1), psychosis and mania (

77 cluding related syndromes, such as delirious mania and mixed affective states.

78 ns of neural activation predict the onset of mania and other mood disorders in high-risk children.

79 ry exposures in a cohort of individuals with mania and other psychiatric disorders as well as in cont

80 FRN as a biological vulnerability marker for mania and pathological risk-taking.

81 ar spectrum features, including items on the mania and psychosis subscales of the Psychiatric Diagnos

82 as a previously unrecognized model of human mania and reveal an important role for CLOCK in the dopa

83 Bipolar mania and schizophrenia are recognized as separate disor

84 e lack of distinct endophenotypes of bipolar mania and schizophrenia has complicated the development

85 ls into question an accepted animal model of mania and should help to develop more accurate human and

86 evidence for interventions in first-episode mania and the lack of agreement among treatment guidelin

87 hase of a unitary psychosis transitioning to mania and then dementia.

88 stability to mitigate recurrent episodes of mania and/or depression.

89 SM-5 criterion would alter the prevalence of mania and/or hypomania.

90 anxiety/depression, affective lability, and mania (and with a parent with older age at mood disorder

91 demarcating 3 groups: mania absent, episodic mania, and chronic mania (manic/hypomanic >1 year).

92 antisocial PD), thought disorder (psychosis, mania, and cluster A PDs), somatoform (somatoform disord

93 f symptoms, including psychosis, depression, mania, and cognitive deficits.

94 Co-occurring substance abuse, psychosis, mania, and cognitive impairment were exclusionary.

95 of schizophrenia, elevated in bipolar (hypo)mania, and contextually misallocated in the positive sym

96 g to the prominence and timing of psychosis, mania, and depression.

97 for Cck in the development and treatment of mania, and describe some of the molecular mechanisms by

98 stent with findings in bipolar I depression, mania, and euthymia, suggesting a physiologic trait mark

99 all of which investigated verapamil in acute mania, and finding no evidence that it is effective.

100 symptoms at baseline, including depression, mania, and insomnia.

101 rn is the risk for mood switch to hypomania, mania, and mixed states.

102 gy, low maternal warmth predicted relapse to mania, and more weeks ill with manic episodes was predic

103 uidelines for the treatment of first-episode mania, and provide a patient's point of view of the care

104 toms.CONCLUSIONBrain lesions associated with mania are characterized by a specific pattern of brain c

105 anxiety/depression, affective lability, and mania are important predictors of new-onset bipolar spec

106 ability, personality changes, psychosis, and mania are less common but equally distressing symptoms t

107 Psychiatric disorders such as addiction and mania are marked by persistent reward seeking despite hi

108 ia competed for dominance with the view that mania arose primarily from accelerated mental processes

109 When the viewpoints shifted away from mania as a primary disorder of judgment, new approaches

110 valproate, the drugs presently used to treat mania associated with BD, rescued the hyperactive phenot

111 We included patients with acute mania associated with bipolar I disorder.

112 to determine the risk of treatment-emergent mania associated with methylphenidate, used in monothera

113 on or anxiety (HR = 6.87, 95%CI 3.97-11.90); mania, bipolar disorder, psychosis, or schizophrenia (HR

114 d a higher prevalence of inguinal hernia and mania/bipolar disorder respectively in male duplication

115 d four unmedicated participants with bipolar mania (BM) (n = 30), bipolar depression (BD) (n = 30), b

116 (BPD), 30 with current bipolar hypomania or mania (BPM), 15 bipolar euthymic (BPE), and 30 healthy c

117 the hyperarousal symptoms characteristic of mania but who lack the well-demarcated periods of elevat

118 During follow-up, 87.8% recovered from mania, but 73.3% relapsed to mania.

119 iffer in time to recurrence of depression or mania, but patients in FFT-A spent fewer weeks in depres

120 Treatment-emergent mania can have substantial negative impact on overall mo

121 exhibit impulsive responding, such as ADHD, mania, chronic substance abuse and schizophrenia.

122 of the 19th century, the mood-based model of mania competed for dominance with the view that mania ar

123 th and onset of several disorders, including mania, confirm multiple case reports and results of smal

124 schizophrenia; and IL-1RA levels in bipolar mania decreased.

125 tioning on individual to compare the rate of mania (defined as hospitalization for mania or a new dis

126 Although mania defines bipolar I disorder, depressive episodes an

127 assessed the incidence rates of depression, mania, delirium, panic disorder, and suicidal behaviors

128 Patients with bipolar mania demonstrated a unique exploratory pattern, charact

129 ogical treatment of phases of BD, including: mania, depression, and long-term recurrences, emphasizin

130 nge, 0.66-0.70) were dimensional measures of mania, depression, anxiety, and mood lability; psychosoc

131 re was time to recurrence of any mood event (mania, depression, or a mixed episode).

132 cluding suicide, suicide attempt, psychosis, mania, depression, panic disorder, and delirium, confusi

133 The components represented dimensions of mania, depression, positive symptoms, anxiety, negative

134 those in the other two groups, and new-onset mania developed in 2 patients in the tDCS group.

135 ogress in developing new pharmacotherapy for mania, developing effective treatments for acute bipolar

136 R-dep) and manic/hypomanic/mixed episode (RR-mania), discontinuation, mortality, and individual adver

137 erience recurrent episodes of depression and mania, disrupting normal life and increasing the risk of

138 gnostically heterogeneous disorder, although mania emerges as a distinct phenotype characterized by e

139 th any mood episodes and 39.6% of weeks with mania episodes, during 8-year follow-up.

140 d age at scan predicted greater future mixed/mania factor score.

141 llele was significantly associated with the "mania" factor, in particular the subdimension "overactiv

142 ugh antipsychotics are effective in treating mania, few antipsychotics have proven to be effective in

143 Given the markedly increased hazard ratio of mania following methylphenidate initiation in bipolar pa

144 ere was a nearly 2-fold increase in rates of mania from ages 13-14 to 17-18 years.

145 The evidence for independence of mania from depression warrants additional scrutiny in th

146 of first-lifetime onset postpartum psychosis/mania from population-based register studies of psychiat

147 e compared with the mania absent and chronic mania groups (12-point and 8-point difference on GAF).

148 The care of people with first-episode mania has been overlooked in comparison with the care of

149 difficult to represent in animals, models of mania have begun to decode its fundamental underlying ne

150 Due to increased impulsivity and risk for mania, however, depressed individuals with bipolar disor

151 kDelta19) have been identified as a model of mania; however, the mechanisms that underlie this phenot

152 r probability of recovery from an episode of mania (HR = 1.713; 95% CI, 1.373-2.137; P < .001), hypom

153 acute treatment and prevention of recurrent mania/hypomania and depression that characterize bipolar

154 polarity were observed for family history of mania/hypomania and multiple past mood episodes.

155 Duration of mania/hypomania showed 2 discontinuities demarcating 3 g

156 MAIN OUTCOME MEASURES: Mania/hypomania with or without depression among those w

157 e psychosis to mood disturbance, duration of mania/hypomania, depression, and psychosis) and 10-year

158 irment of cognitive function, depression, or mania; impairment of reproductive and sexual function; a

159 lity is a diagnostic indicator for pediatric mania in bipolar disorder.

160 re are limited data on the manifestations of mania in general community samples of adolescents.

161 This is highly consistent with mania in humans.

162 t to share face and predictive validity with mania in humans.

163 orrelates associated with treatment-emergent mania in patients receiving adjunctive antidepressant tr

164 nic risk score and the clinical dimension of mania in SCZ patients.

165 ne the general epidemiology of first-episode mania in the context of bipolar disorder, the natural hi

166 hm in patients with first-onset psychosis or mania in the postpartum period.

167 the YMRS items predicted treatment-emergent mania in this sample: increased motor activity, speech,

168 regarding the efficacy and safety of ECT in mania, including related syndromes, such as delirious ma

169 We included factors of mixed/mania, irritability, and anxiety/depression (29 months p

170 Mania is a serious neuropsychiatric condition associated

171 Mania is characterised by increased impulsivity and risk

172 BACKGROUNDAlthough mania is characteristic of bipolar disorder, it can also

173 The development of the modern concept of mania is explored by a review and analysis of 28 psychia

174 Effective treatment of acute or dysphoric mania is provided by modern antipsychotics, some anticon

175 ce a widely used standalone intervention for mania, is no longer considered a first-line treatment.

176 ty was assessed using independent cohorts of mania lesions derived from clinical chart review (n = 15

177 The mania like-behaviors mostly depended on dopamine, becaus

178 wly developed mouse model of ouabain-induced mania-like behavior could provide a perspective tool for

179 pha activity in the ventral midbrain induced mania-like behavior in association with a central hyperd

180 We describe a mouse model of ouabain-induced mania-like behavior.

181 al NAC phase signaling may contribute to the mania-like behavioral manifestations that result from di

182 r gross neural circuit function and generate mania-like behaviors in Clock-Delta19 mice.

183 The mania-like behaviors, including the sleep loss, were rev

184 5alphaR mediates a number of psychosis- and mania-like complications of SD through imbalances in cor

185 n the central nervous system, known to cause mania-like hyperactivity in rats.

186 d inhibition from VTA(Vgat) neurons produces mania-like qualities (hyperactivity, hedonia, decreased

187 eurons generated persistent wakefulness with mania-like qualities: locomotor activity was increased;

188 of either irritability or short episodes of mania-like symptoms in youth.

189 ther irritability or short-lived episodes of mania-like symptoms is still small.

190 en with short (less than 4 days) episodes of mania-like symptoms seem to progress to classical (Type

191 re chronic irritability or short episodes of mania-like symptoms, are common, impairing and a topic o

192 ith severe irritability or short episodes of mania-like symptoms.

193 1), and IL-1 receptor antagonist (p value in mania < .001 and euthymia = .021) were significantly ele

194 s: mania absent, episodic mania, and chronic mania (manic/hypomanic >1 year).

195 individual patterns of activity suggest that mania may be better characterized by differences in robu

196 of symptoms of depression or of hypomania or mania, measured by the Inventory of Depressive Symptomat

197 ategories based on symptomatic presentation--mania, melancholia and paranoia--all derived from the be

198 es are remission, subsyndromal and syndromal mania, mixed states or depression.

199 cation (excluding patients with hypomania or mania, mixed symptoms, or rapid cycling).

200 face validity of the MSN strain as a complex mania model, adding sexual dimorphism, an altered diurna

201 ach involves analysis of naturally occurring mania models including an inbred strain our lab has rece

202 The principal mania models involve transgenic manipulations or treatme

203 ed from lesion locations not associated with mania (n = 79).

204 of schizophrenia (N=65), bipolar disorder or mania (N=37), depressive psychosis (N=39), or other psyc

205 gnificantly higher risks of both first-onset mania (odds ratio (OR) for abuse: 2.23; 95% confidence i

206 nfluences the risk for psychotic features in mania of bipolar disorder patients.

207 etime bipolar I or II disorder and 1.7%, for mania only.

208 ate of mania (defined as hospitalization for mania or a new dispensation of stabilizing medication) 0

209 or mania symptom load at the study entry and mania or depression symptom severity at the 3-month foll

210 ifferentiate between disturbances related to mania or depression, which is necessary to understand th

211 with an increased risk of treatment-emergent mania or hypomania (0.926 [0.576-1.491], p=0.753), but 5

212 d significantly higher rates of subthreshold mania or hypomania (13.3% compared with 1.2%), manic, mi

213 (N=45), and those who had treatment-emergent mania or hypomania (N=46).

214 sorder with extreme mood swings that include mania or hypomania and depression.

215 There were 7 episodes of treatment-emergent mania or hypomania, 5 occurring in the combined treatmen

216 onse, clinical remission, treatment-emergent mania or hypomania, and tolerability (using dropout rate

217 with an increased risk of treatment-emergent mania or hypomania.

218 ts with major depression predicted new-onset mania or hypomania.

219 sodes of major depression and in episodes of mania or hypomania.

220 iated with antidepressant treatment-emergent mania or hypomania.

221 relative to healthy participants, those with mania or mixed mania would (1) exhibit incremental decre

222 rred within the first postpartum month, with mania or psychosis having an earlier onset than depressi

223 reatment: 2.10; CI=1.55, 2.83) and recurrent mania (OR for abuse: 1.55; CI=1.00, 2.40; OR for maltrea

224 a and MDEs (OR=.7, CI:.5-1.1), psychosis and mania (OR=1.0, CI:.4-2.7) or psychosis and MDEs (OR=1.0,

225 OR)=2.9, confidence interval (CI): 1.1-7.7), mania (OR=6.4, CI: 2.2-18.7) and MDEs (OR=2.0, CI: 1.5-2

226 ession or anxiety, psychosis, schizophrenia, mania, or bipolar disorder, personality disorder, substa

227 at environmental exposures can contribute to mania pathogenesis.

228 ere strikingly similar to those of the human mania phenotype and may thus serve as a valid mouse mode

229 tion of the dopamine transporter matched the mania phenotype better than the effects of amphetamine,

230 The clinical significance of mania plus depression as demonstrated by a 1 in 5 suicid

231 ant outcomes (i.e., criminality, depression, mania, psychosis).

232 , more rare but severe complications such as mania, psychotic symptoms, or delirium need individual p

233 on Rating Scale (MADRS) (range, 0-60), Young Mania Rating Scale (YMRS) (range, 0-44), Social and Occu

234 y of Depressive Symptomatology and the Young Mania Rating Scale (YMRS) at baseline and bimonthly inte

235 linician-Rated Version (IDS-C) and the Young Mania Rating Scale (YMRS) were administered at each visi

236 ton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) were used to evaluate clinical

237 n Rating Scale for Anxiety (HRSA), and Young Mania Rating Scale (YMRS).

238 Efficacy was assessed with the Young Mania Rating Scale (YMRS).

239 ween baseline and change scores on the Young Mania Rating Scale (YMRS; range 0-60) up to 3 weeks for

240 Hamilton Depression Rating Scale, and Young Mania Rating Scale at baseline and week 14.

241 hange from baseline to endpoint in the Young Mania Rating Scale total score was the primary outcome m

242 an adverse effects questionnaire, the young mania rating scale, and cognitive assessment.

243 Positive and Negative Syndrome Scale, Young Mania Rating Scale, and Global Assessment of Functioning

244 (Positive and Negative Syndrome Scale, Young Mania Rating Scale, and Global Assessment of Functioning

245 ypical Depression Supplement (SIGH-ADS), the Mania Rating Scale, and the Pittsburgh Sleep Quality Ind

246 ent in manic symptoms, assessed by the Young Mania Rating Scale, was also observed, in addition to ot

247 ilton Depression Rating Scale, and the Young Mania Rating Scale.

248 rief Psychiatric Rating Scale, and the Young Mania Rating Scale.

249 essive symptomatology self-report, and young mania rating scale.

250 y of Depressive Symptomatology and the Young Mania Rating Scale.

251 SD) can trigger or exacerbate psychosis- and mania-related symptoms; the neurobiological basis of the

252 On mania-related tests, BAG1 TG mice recovered much faster

253 nitial severity range in patients with acute mania remains unclear.

254 ith depression and 50.9% of respondents with mania reporting severe role impairment.

255 mental processes and to a lesser degree that mania resulted from psychomotor excitation.

256 =108) of the sample experienced hypomania or mania, resulting in revision of diagnoses for 12.2% to b

257 he Parent General Behavior Inventory-10 Item Mania Scale (PGBI-10M)) at a mean of 14.2 months follow-

258 m was associated with a greater reduction in mania scores over 9 weeks.

259 teresting dispositional phenomena related to mania seen in MSN mice.

260 istory of childhood maltreatment had greater mania severity (six studies, 780 participants; odds rati

261 , p = .04) activation to RPE and future hypo/mania severity trajectory: the interaction between great

262 thickness, greater self-reported depression, mania severity, and age at scan predicted greater future

263 associated with a shallower increase in hypo/mania severity, whereas the interaction between greater

264 n to RPE was associated with increasing hypo/mania severity.

265 The history of mania shares some important similarities and differences

266 e relationship between antidepressant use or mania symptom load at the study entry and mania or depre

267 use was associated with significantly higher mania symptom severity at the 3-month follow-up.

268 e insight into brain regions responsible for mania symptoms and identify therapeutic targets.METHODSL

269 vity that lends insight into localization of mania symptoms and potential therapeutic targets.FUNDING

270 NCAN preferentially affected mania symptoms in humans.

271 systematic care interventions effective for mania symptoms.

272 effects of therapeutic brain stimulation on mania symptoms.CONCLUSIONBrain lesions associated with m

273 tes previously reported to induce or relieve mania symptoms.RESULTSLesion locations associated with m

274 identify defining characteristics of bipolar mania that are distinct from those of schizophrenia.

275 rugs are effective in the acute treatment of mania; their efficacy in the treatment of depression is

276 The increased risk of treatment-emergent mania was confined to patients on antidepressant monothe

277 From 1780 until the 1820s, mania was consistently viewed as a disorder of reasoning

278 oms at baseline with subsequent hypomania or mania was determined in survival analyses using Cox prop

279 atients taking mood stabilizers, the risk of mania was lower after starting methylphenidate (hazard r

280 mood stabilizer, no acute change in risk of mania was observed during the 3 months after the start o

281 ATPase alpha3 Myshkin (Myk/+) mouse model of mania was performed.

282 However, no risk of mania was seen in patients receiving an antidepressant w

283 he next 30 years, the consensus shifted, and mania was understood to be largely a disorder of elevate

284 first episodes, second and third episodes of mania were characterized by psychosis, daily (ultradian)

285 were observed when only hospitalizations for mania were counted.

286 their index major depressive episode and/or mania were divided into residual vs asymptomatic recover

287 toms.RESULTSLesion locations associated with mania were heterogeneous and no single brain region was

288 gets.METHODSLesion locations associated with mania were identified using a systematic literature sear

289 eficits in patients with bipolar disorder or mania were less pervasive but evident in performance sco

290 with depression alone, whereas correlates of mania were similar among those with mania with or withou

291 on of mood symptoms have stronger effects on mania, whereas treatments that emphasize cognitive and i

292 haviors of children at high and low risk for mania while they anticipate and respond to reward and lo

293 isk of delirium/confusion/disorientation and mania, while younger patients were at higher risk of sui

294 increased dopaminergic neurotransmission and mania, whilst increased striatal dopamine transporter (D

295 Twelve-month rates of mania with and without depression were 2.2% and 1.3%, re

296 ether with high rates of clinical overlap of mania with anxiety and substance use disorders provide a

297 Mania with depression was associated with a greater numb

298 lates of mania were similar among those with mania with or without depression.

299 of bipolar disorder, the natural history of mania (with an emphasis on its recurrent nature), curren

300 lthy participants, those with mania or mixed mania would (1) exhibit incremental decrements in sustai